Faeth Therapeutics
FTH
26 hedge funds and large institutions have $4.71M invested in Faeth Therapeutics in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 3 closing their positions.
20% more capital invested
Capital invested by funds: $3.92M → $4.71M (+$791K)
0.08% more ownership
Funds ownership: 0.43% → 0.51% (+0.08%)
0% more funds holding
Funds holding: 26 → 26 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
+$571K |
| 2 |
Morgan Stanley
New York
|
+$190K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$130K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$61.2K |
| 5 |
Millennium Management
New York
|
+$4.38K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$70.2K |
| 2 |
WSL
Western Standard LLC
Los Angeles,
California
|
-$68.7K |
| 3 |
VF
Virtu Financial
New York
|
-$39K |
| 4 |
E
Ergoteles
New York
|
-$27.9K |
| 5 |
Two Sigma Investments
New York
|
-$23.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HI
26
Harbour Investments
Madison,
Wisconsin
| $5 | – | – | – |
|
|
WSL
27
Western Standard LLC
Los Angeles,
California
| – | -$68.7K | -2,306 | Closed |
|
|
VF
28
Virtu Financial
New York
| – | -$39K | -1,303 | Closed |
|
|
FA
29
Fiduciary Alliance
Greenville,
South Carolina
| – | -$75 | -3 | Closed |
|
30
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$89 | +3 | New |
|
FTH Hedge Fund Activity: Q1 2023 in Review
26 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Faeth Therapeutics (FTH) for Q1 2023, worth a combined $4.71M — up 20% from $3.92M a quarter earlier.
Fund positioning in FTH was balanced in Q1 2023: 3 funds opened new positions, 3 closed out, 6 added to existing stakes and 7 trimmed.
The largest buyer was Newtyn Management, adding an estimated $571K. The largest seller was Renaissance Technologies, cutting an estimated $70.2K.
- 26 institutional investors held Faeth Therapeutics (FTH) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $4.71M of Faeth Therapeutics stock for Q1 2023, up 20% quarter-over-quarter.
- 3 funds opened new Faeth Therapeutics positions in Q1 2023 and 3 closed out, a net change of 0 holders.
- The largest Faeth Therapeutics buyer in Q1 2023 was Newtyn Management, an estimated $571K added.
- The largest Faeth Therapeutics seller in Q1 2023 was Renaissance Technologies, an estimated $70.2K sold.
Based on aggregated 13F filings for Q1 2023.